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ABSTRACT  
Objective: The objective of the study was to assess the pill burden (PB), drug class distribution and financial burden for buying medicines in 
different treatment modalities of chronic kidney disease (CKD) patients.  
Methods: A prospective, cross-sectional study was performed in 244 CKD patients and they were divided into 4 groups as follows: pre-dialysis 
patients (stages 1-5) as group 1, hemodialysis (HD) patients as group 2, peritoneal dialysis (PD) patients as group 3 and renal transplant recipient 
(RTR) patients as group 4. Data was collected in pre-designed form through direct patient interaction. 
Results: Out of 244 CKD patients, PB considering the total number of pills/d in different modalities is 12±5 in pre-dialysis, 10±3 in HD, 13±5 in PD, 
14±7 in RTR and for the number of drug classes/d in different modalities is 7±3 in pre-dialysis, 7±2 in HD, 8±3 in PD and 9±3 in RTR. On average 
mean PB in a number of pills/d is 12±5 and number of drug classes/d is 8±3. Among all the patients, the RTR individuals are having high medicinal 
expenditure in comparison to the other modalities. 
Conclusion: PB for the number of pills/d is highest in RTR and almost similar in different modalities. Great improvement in reducing the PB as well 
as financial burden directly or indirectly improves the patient compliance as well as the quality of life. 
Keywords: Chronic kidney disease, Pill burden, Drug class distribution, Financial burden, Predialysis, Hemodialysis, Peritoneal dialysis, Renal 
transplant recipient  




Chronic kidney disease (CKD) remains a major global public health 
problem with increasing prevalence, incidence and tremendous cost 
with poor outcome [1]. In India, the prevalence rate of CKD was 
estimated to be 12.5% [2]. As per global burden of disease study, 
CKD is estimated to be 12th among all causes of death and men are 
more prominently affected. In western countries, hypertension 
(HTN) and diabetes mellitus (DM) was found to be a 2/3rd
PB refers to taking more number of pills (tablets or capsules and 
other conventional dosage forms) that a patient takes on a frequent 
basis. Therefore, high PB increases the chances of hospitalization, 
medication errors and elevated costs not only for pharmaceuticals 
as well as treatment for adverse events [5]. Several studies have 
reported that dialysis patients are expected to have a high PB due to 
severe chronic illness combined with multiple co-morbidities. It has 
been reported that average dialysis patients take 10 to 12 different 
types of medications [6, 7]. In chronic conditions, complex 
medication regimens with high PB lead to non-adherence [8-11]. 
CKD patients are prone to a greater chance of drug-related problems 
not only by the pharmacokinetic variations in renal excreted drugs 
but also by the use of more number of medications to manage the 
complications and co-morbidities in CKD. 
 cause of 
CKD [3]. Likely in India, DM and HTN currently accounted 40-60% 
cause of CKD [4]. CKD patients are more prone to high pill burden 
(PB) because of multiple co-morbidities and indirectly reducing the 
adherence to therapy. 
In middle and low-income countries, the financial burden is the main 
concern for the patients who require treatment for dialysis or 
kidney transplantation. In 2009, the mumbai kidney foundation 
(MKF) reports gave a perception in end-stage renal kidney disease 
(ESRD) cost management stating that each hemodialysis (HD) 
session in Indian government and corporate hospitals setup would 
range in between around INR Rs. 150 to Rs. 2000. Annual 
expenditure for dialysis in India and United States (US) would cost 
around Rs. 140000 ($3000) and $60000 respectively. Compared to 
other countries, even though there is less expenditure for dialysis in 
India, most of the population (90%) cannot afford it due to economic 
issues. Whereas kidney transplantation cost ranges from Rs. 50 000 
in government hospitals and Rs. 300000 in some private hospitals 
and monthly maintenance for post-transplant drugs would cost 
around Rs. 10000 (Rs. 120000/y) [12]. Therefore, it is difficult to 
afford for many people. In CKD, direct healthcare expenditure is 
greater in patients with anemia than in those without [13] and 
quality of life issues (ex. fatigue, reduced productivity) are common 
[14,15]. Recently in many Indian hospitals, so many schemes are 
being implemented. In the present scenario, in many of the states in 
developing countries, government and non-government 
organizations have come forward to help the patients in providing 
subsidized or free dialysis. However, the financial burden for the 
medicines is variable in CKD patients. Keeping this situation in view, 
we have undertaken this study to know the drug class distribution, 
PB and financial burden for buying medicines in CKD patients 
among different treatment modalities. 
MATERIALS AND METHODS 
This was a prospective, cross-sectional study performed in the 
department of nephrology at Sri Venkateswara Institute of Medical 
Sciences (SVIMS), a tertiary care teaching hospital, Tirupati for a period 
of six months from April 2017 to September 2017, which was approved 
by the institutional ethics committee clearance (622/IEC/2017). A total 
of 244 patients diagnosed with CKD at all stages were included. Among 
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244 CKD patients, based on the modality of treatment, 107 patients were 
under stage 1-5(pre-dialysis), 58 were in HD, 52 were in peritoneal 
dialysis (PD) and 27 were in renal transplant recipient (RTR) as per the 
national kidney foundation/kidney disease outcomes quality initiative 
(NKF/KDOQI) guidelines [16]. Pregnant women, children below 18 y, 
psychiatric patients and unwilling participants were excluded. Patients 
information was collected by using a well-designed data collection form 
which was kept confidential. Patient’s information was collected after 
explaining the study and receiving their consent by using informed 
consent form. Topical, inhaled, injectable medications were not included 
in PB. 
Study procedure 
Patients were divided into 4 groups as follows: pre-dialysis CKD 
patients (stages 1-5) as group 1, CKD patients on HD as group 2, CKD 
patients on PD as group 3 and RTR patients as group 4. The suitable 
data collection form was used to collect all the necessary 
information to evaluate PB and financial costs for buying medicines. 
Statistical analysis 
All cases information were collected and recorded in microsoft excel 
sheet. Data were expressed in mean±standard deviation (SD). Values 
were presented as counts and percentage. An unpaired t-test was used 
to compare between two groups. Comparison across the groups was 
performed by using one-way ANOVA followed by post hoc analysis. A p 
value of<0.05 was found to be statistically significant.  
RESULTS 
The demographic result data were shown in table 1. Out of 244 CKD 
patients reviewed, 66 % were males and 34% were females. In male 
CKD patients, under the age group of 18–59 y (n=96) constituted 39% 
and under the age group of ≥60 y (n=66) constituted 27 % of patients 
respectively. In female CKD patients, under the age group of 18–59 y 
(n=54) constituted 23% and under the age group of ≥60 y (n=28) 
constituted 11% of patients respectively. Dependent CKD patients 
(n=100) were lesser than independent CKD patients (n=144). 
  
Table 1: Demographic data of study patients 
Demographic data Males (n) Females (n) 









Dependents 51 49 
Independents 111 33 






Government 58 31 
Private 69 39 
 
Based on etiology of CKD, the total patients were divided into two 
subgroups, i.e., diabetic CKDs and non-diabetic CKDs which include 
HTN, chronic glomerulonephritis (CGN), chronic interstitial 
nephritis (CIN) and autosomal dominant polycystic kidney disease 
(ADPKD) [table 2]. While comparing occupational status and 
etiological factors of CKD we found that diabetic CKD patients were 
more in employment group and non-diabetic CKD (HTN and CGN) 
patients were more in the agricultural group. 
 
Table 2: Etiology of CKD patients of the present study 
Etiology No. of patients(n) Percentage (%) 
DM 103 42 
HTN and CGN 117 48 
CIN 19 8 
ADPKD 5 2 
DM-diabetes mellitus, HTN-hypertension, CGN-chronic glomerulonephritis, CIN-chronic interstitial nephritis, ADPKD-autosomal dominant 
polycystic kidney disease 
 
One-way ANOVA followed by post hoc bonferroni analysis was 
performed to assess the drug classes and the number of pills/d in 
different modalities and unpaired t-test was performed to assess PB in 
different modalities between the age group 18–59 y and ≥60 y [table 
3]. When compared with other modalities, mean PB for drug classes/d 
was found to be highest (9±3) and mean PB for a total number of pills 
was also found to be highest (14±7) in RTR patients [table 3]. The 
results showed that there was no significance between mean pills/d 
among different modalities between the age group 18–59 y and ≥60 y 
except in PD patients which showed significance (p=0.002*) and for 
drug classes/d also showed no significance between age groups except 
in HD which showed significance (p= 0.013*). 
  
Table 3: Mean pill burden for number of pills and drug classes per day across different modalities 
Modalities Age N Drug classes/d p value p value vs pre-dialysis Total pills/d p value p value vs pre-dialysis 
Pre-dialysis 18-59 48 7±3   13±5   
≥60 59 7±2  12±4  
mean 54±5 7±3 1.000 12±5 † 0.252
HD 
† 
18-59 39 7±1  0.160 11±2 †  0.426 
≥60 
† 
19 8±2  10±3  
mean 29±10 7±2 0.013* 10±3 0.136
PD 
† 
18-59 36 8±3  0.934 14±5 †  0.939 
≥60 
† 
16 7±2  10±1  












0     
mean  9±3 1.000 14±7 † 0.517† 
Data are given as number (n) of patients, values expressed in mean±standard deviation, Significant at *p<0.05 probability level, †NS-not significant 
at the 0.05 probability level, p-value by using one-way ANOVA between age groups and p-value vs pre-dialysis using post hoc bonferroni analysis 
between different modalities., Abbreviations: HD-hemodialysis, PD-peritoneal dialysis, RTR-renal transplant recipient 
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Across different modalities, the PB for different classes of medications 
was shown in fig. 1. The unpaired t-test was used to find the significant 
difference between different drug classes of medications and mean 
pills/d in HD and PD [table 4]. It was observed that there was a 
statistically significant between different drug classes of medications 
and mean pills/d in HD and PD (p<0.05*). 
 














18-59 39 36 7±1 8±3 0.007* 11±2 14±5 0.001* 
≥60 19 16 8±2 7±2 0.033* 10±3 10±1 1.000
 
† 
 Mean 7±2 8±3 0.033* 10±3 13±5 0.002* 
*p<0.05 is considered statistically significant (unpaired t-test), †
 
NS-Not significant at the 0.05 probability level, data are given as number (n) of 
patients, values expressed in mean±standard deviation, Abbreviations: HD-hemodialysis, PD-peritoneal dialysis 
 
Fig. 1a: Drug class distribution in predialysis 
 
Fig 1a. Others include: CAD, hyperlipidemic drugs, hypothyroidism 
drugs, hyperthyroidism drugs, anti-emetic drugs, laxatives, 
hematinics, uric acid inhibitors, COPD (rare patients). 
Abbreviations: coronary artery disease (CAD), chronic obstructive 
pulmonary disease (COPD) 
Fig 1b. Others include: CAD, hyperlipidemic drugs, hypothyroidism 
drugs, anti-emetic drugs, laxatives, hematinics, uric acid inhibitors, 
COPD (rare patients) 
Abbreviations: coronary artery disease (CAD), chronic obstructive 
pulmonary disease (COPD) 
 
 
Fig. 1b: Drug class distribution in HD 
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Fig. 1c: Drug class distribution in PD 
 
 
Fig. 1d: Drug class distribution in RTR 
 
Fig 1c. Others include: CAD, hyperlipidemic drugs, hypothyroidism 
drugs, anti-emetic drugs, laxatives, hematinics, uric acid inhibitors, 
COPD (rare patients) 
Abbreviations: Coronary artery disease (CAD), chronic obstructive 
pulmonary disease (COPD) 
Immunosuppressants include prednisolone, mycophenolate mofetil, 
tacrolimus, sirolimus,  
Fig 1d.Others include: CAD, hyperlipidemic drugs, hypothyroidism 
drugs, hematinics, antibiotics, COPD (rare patients) 
Abbreviations: coronary artery disease (CAD), chronic obstructive 
pulmonary disease (COPD) 
Average monthly medicinal expenditure for the CKD patients among 
different modalities was shown in table 5. The results showed that, 
in CKD patients, RTR patients were found to have the highest cost 
for buying medicines when compared to other modalities. 
  
Table 5: Average monthly medicinal expenditure for buying pills in CKD patients between the modalities 
Modalities Average medicinal 
expenditure (in rupees) 
p-value (pre-











Pre dialysis 2270±1000 0.634 0.848† 0.001* †    
HD 2195±900 0.634  †  0.510 0.001* †  
PD 2300±750  0.848  † 0.510  † 0.001* 
RTR 5200±2060   0.001*  0.001* 0.001* 
*p<0.05 is considered statistically significant (one-way ANOVA), †
 
NS-not significant at the 0.05 probability level, values expressed in mean±standard 
deviation (SD), Abbreviations: HD-hemodialysis, PD-peritoneal dialysis 
DISCUSSION 
Globally, CKD is becoming a major health problem for the public.  
Thus, patients with CKD are an ideal target for interventions aimed 
at reduction of morbidity and mortality. This study focused on drug 
classes, daily total PB and financial burden for buying medicines in 
different modalities in CKD patients. 
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CKD management contributes to significant financial burden 
together on health systems, patients and their households. In 
developing countries, such as India, kidney failure cases were 
increased mainly in the elderly populations [17]. In middle-income 
countries, the financial burden is the major concern for the people 
who require treatment for dialysis or kidney transplantation. In 
patients with CKD belonging to low-income countries, the morbidity 
and mortality rate per annum found to be high as they cannot be 
able to afford the treatment for kidney failure [18]. 
This present study data showed that CKD burden was more in the 
age group 18–59 y when compared to age group ≥60 y and males 
were more predominant than females. The etiological factor in CKD 
found to be DM followed by HTN, CGN, CIN and ADPKD. We found 
diabetic CKD was more in the employed group while non-diabetic 
CKD (HTN and CGN) was more in the agricultural group. Female CKD 
patients found to be more dependent than males. In our study, based 
on the modality of treatment majority of the CKD patients belong to 
stage 1-5 (pre-dialysis). Comorbid conditions such as cardiovascular 
disease (CVD), ischemic heart disease (IHD) and peripheral artery 
disease (PAD) have shown to be associated with increased 
hospitalizations among ESRD [19, 20] and pre-dialysis patients [21] 
that might enhance the financial burden in these populations. 
Multiple factors play a key role in adherence to pharmacological 
therapy in CKD population. One of the barriers to non-adherence is a 
financial burden in this population. The link between PB to 
adherence and outcomes is an important role for the general 
population in clinical practice setting [22]. 
This study was focused to find out the extent of PB on patients 
belonging to various stages of CKD on different treatment modalities 
including pre-dialysis, HD, PD, post-transplant groups (RTR). With 
regard to PB, represented as number of pills/d we observed that it 
was 12±5 in pre-dialysis, 10±3 in HD, 13±5 in PD, 14±7 in RTR and 
we did not find any statistical difference but when compared with 
age groups (18-69 y and ≥60  y) also showed no significance except 
in PD patients. With regard to different drug classes/d, we observed 
that it was 7±3 in pre-dialysis, 7±2 in HD, 8±3 in PD, 9±3 in RTR and 
we did not find any statistical difference but when compared with 
age groups (18-69 y and ≥60  y) also showed no significance except 
in HD patients. Our observation suggests that the average PB in the 
number of pills/d is 12±5 (7-17 pills/d) and average PB in the 
number of drug classes/d is 8±3 (5-11 drug classes/d) among 
different modalities. A similar study was conducted in the year 2009 
by Kathrine Parker et al., in the US and their study reported that HD 
patients had a significantly lower PB (11±7 pills/d) compared with 
PD patients(16±7 pills/d) [23]. A similar study was conducted in the 
year 2011-2012 by Uma Rani Adhikari et al., in two tertiary care 
hospitals, Kolkata who were running renal transplant program, their 
study mean PB ranged between 10-21 pills/d [24]. The 
pharmacological therapy varies with an average number of 
medicines given to different modalities. In the present study, it was 
found that there is a significant difference (*p<0.05) observed in 
average drug classes/d and average pills/d between HD and PD. 
In addition to the medications that are taken in pre-dialysis, HD and 
PD patients, the RTR patients require immunosuppressant’s and 
anti-hypertensive drugs followed with other medications which are 
required for them were given that might contribute to more number 
of pills/d compared to other modalities. Majority of post renal 
transplantation medication include triple immunosuppressive i.e., 
prednisolone, mycophenolate mofetil, tacrolimus or sirolimus. 
Sirolimus usage was limited to patients from whom from tacrolimus 
was been removed for medical reasons. In a study by Kathrine 
Parker et al., also reported that more number of RTR patients 
consumes anti-hypertensive medications and hence observed more 
burden to consume medications in this group [23]. 
With regard to financial burden in the present study, all the patients 
were been supported for dialysis treatment indicating that there 
was no expenditure from the patients towards dialysis procedure. 
However, the financial burden for the medicinal expenditure was 
variable. The CKD patients on RTR were been found to have financial 
burden when compared to other modalities. Thus, from the present 
study it was observed that all the CKD patients were financially 
being supported completely for dialysis. Henceforth if likely 
extension of the similar support for the provision of drugs for all the 
CKD patients in various stages can be considered to reduce the 
burden on pharmaceutical costs not only for the patients but also to 
the caregivers of the family which increases the adherence to 
medications. On a cross-sectional study basis, a onetime impromptu 
expression on approximate expenditure they incur on monthly basis 
for the drugs was been considered. However, the patients do receive 
support in the form of reimbursement in certain of the categories 
and supports from charity organizations for some categories. 
Therefore, the information provided on the expenditure is an 
approximate figure. 
CONCLUSION 
From the present study, we conclude that the monthly medicinal 
costs in CKD patients with pre-dialysis, HD and PD were variable. It 
is observed that the CKD patients on RTR were having high financial 
burden/costs for medicines. Thus, measures to provide free 
medicines or subsidized medicines might be considered that reduce 
the pharmaceutical costs and increases the adherence to therapy. 
Keeping this observation in view in order to reduce PB, the practice 
of prescribing fixed drug dose combinations, extended release or 
sustained release formulations and the drugs with long-acting 
agents and prescribing medicines based on their absolute indication 
can be the logical strategies to reduce the pill number and also drug 
classes. In addition to above, the practice of prescribing utilization of 
generic drugs may significantly reduce the expenditure on drugs, 
which ultimately reduce the financial burden. An additional support 
of Rs. 3000 to 5000 per patient would help in relieving their 
financial burden and indirectly encouraging them to utilize the 
savings to be used for family support, compliance to therapy, better 
nutritional support and reducing the financial burden on a patient. 
This understanding would help the supporting organizations to 
include a fiscal consideration while planning policy issues to meet 
the disease treatment requirements holistically. 
Limitation of the study 
The main limitation of the present study was that it was been 
carried out only for a short duration. Adherence was not studied 
which remains the main problem in chronic condition patients, 
especially with large PB. Another main limitation was that not all 
healthcare cost components were included in the present study. 
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